A5033346506- Renal cell carcinoma treatment
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Immune Cell Function and Interaction
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Retinoids in leukemia and cellular processes
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Hematological disorders and diagnostics
- Blood groups and transfusion
- Colorectal Cancer Treatments and Studies
- Melanoma and MAPK Pathways
- Cancer Diagnosis and Treatment
Cancer Research Foundation
2015-2025
Lady of Mercy Medical Center
2007-2024
Kids' Brain Tumor Cure Foundation
2014-2024
Roosevelt Hospital
2023
New York Medical College
2006-2021
St. Luke's-Roosevelt Hospital Center
2011-2021
New York Proton Center
2019
Montefiore Medical Center
1997-2017
Lung Cancer Research Foundation
2016
Xilinx (United States)
2015
Purpose To evaluate the efficacy, safety, and pharmacokinetics of multiple doses CCI-779, a novel mammalian target rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC). Patients Methods (n = 111) were randomly assigned to receive 25, 75, or 250 mg CCI-779 weekly as 30-minute intravenous infusion. evaluated for tumor response, time progression, survival, adverse events. Blood samples collected determine pharmacokinetics. Results produced an objective...
Purpose Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus monotherapy was conducted. Patients Methods with previously untreated, clear-cell RCC were randomly assigned receive either (10 mg/kg intravenously every 2 weeks) (9 million U subcutaneously three...
The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma.Patients were stratified for bone liver metastases, primary tumor place, Eastern Cooperative Oncology performance status 0 or 1 then randomly assigned receive either (5 MIU/m(2) subcutaneously every 8 hours three doses on day 1, daily 5 days/wk 4 weeks) IFN times...
The National Cancer Institute (NCI) Extramural IL2/LAK Working Group treated 93 patients with 114 cycles of high-dose intravenous (IV) interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells in three phase II trials. Thirty-six had metastatic melanoma, 35 renal cell cancer, 22 colorectal cancer. All a Karnofsky performance status greater than or equal to 80% normal laboratory tests organ function, received no more one prior form immunotherapy chemotherapy. Objective responders were...
Purpose To investigate the efficacy and safety of axitinib, an oral, potent, selective inhibitor vascular endothelial growth factor (VEGF) receptors 1, 2, 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib. Patients Methods In this multicenter, open-label, phase II study, sorafenib-refractory mRCC received a starting dose axitinib 5 mg orally twice daily. A one-arm, single-stage design was used estimate...
Abstract BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. METHODS: In this nonrandomized, open‐label expanded access program, 2504 from the United States and Canada were treated oral 400 mg twice daily. Safety efficacy explored overall in subgroups of including those no prior therapy, nonclear (nonclear cell) RCC, brain metastases, bevacizumab treatment, elderly...
Taxol, a plant alkaloid with promise as an antineoplastic agent, produced predominantly sensory neuropathy in 16 of 60 patients treated two phase I trials. This occurred only at taxol doses greater than 200 mg/m<sup>2</sup>. Symptoms typically started 1 to 3 days following treatment, beginning the hands and feet simultaneously most patients. Electrophysiologic data suggests both axonal degeneration demyelination. previously undefined neurotoxic likely results from taxol9s unique ability...
This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC).Eligibility requirements were resected locally advanced (LA; T3b-4 or N1-3) metastatic (M1) RCC, no prior systemic therapy, and excellent organ function. Randomized assignment was to one course of IL-2 (600,000 U/kg every 8 hours on days 1 5 15 19 [maximum 28 doses]) observation. The study designed powered show an...
A recombinant human TNF receptor Fc fusion protein (rhuTNFR:Fc) was assessed for antiarthritic activity using murine type II collagen-induced arthritis in mice. DBA/1 mice were immunized with bovine collagen and treated rhuTNFR:Fc either from day 21 to 28 (preventative protocol), or after disease onset fourteen days (therapeutic protocol). Control received sterile saline serum albumin injections. rhuT-NFR:Fc treatment significantly reduced both the incidence severity of preventative...
Taxol, a plant product, has significant activity against certain rodent and human xenograft tumors. It promotes microtubule assembly in vitro, contrast to vinca alkaloids, which inhibit assembly. In this phase I study, taxol was administered as 24-hour continuous intravenous (IV) infusion 65 courses 26 patients. A premedication regimen of dexamethasone, cimetidine, diphenhydramine used prevent the acute hypersensitivity reactions observed previous studies taxol. Only one episode mild stridor...
Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy adoptive immunotherapy high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two who received all components therapy are evaluable for response, toxicity. Sites disease included lung, liver, subcutaneous nodules, intra-abdominal metastases. One complete response (CR) five partial responses (PRs) resulted from treatment (19% rate). The median duration was 5 months,...
To determine the toxicity, maximum-tolerated dose (MTD), and pharmacokinetics of recombinant human CD40 ligand (rhuCD40L) (Avrend; Immunex Corp, Seattle, WA), suggested in preclinical studies to mediate cytotoxicity against CD40-expressing tumors immune stimulation.Patients with advanced solid or intermediate- high-grade non-Hodgkin's lymphoma (NHL) received rhuCD40L subcutaneously daily for 5 days a phase I dose-escalation study. Subsequent courses were given until disease...
LBA4 Background: Temsirolimus (TEMSR, CCI-779) is a specific inhibitor of mTOR, signaling protein that regulates cell growth and angiogenesis. In single-agent, phase 2 study, TEMSR administration to heavily pretreated patients (pts, n = 111) with adv RCC resulted in median overall survival (OS) 15.0 mos (Atkins et al, J Clin Oncol 2004). Retrospectively, 49 pts were categorized poor-risk group (Motzer 2002). The TEMSR-treated this had 1.7-fold longer OS than the first-line, IFN-treated,...
Forty-seven patients with metastatic malignant melanoma were treated two 5-day cycles of 100,000 U/kg recombinant interleukin-2 (IL-2) intravenously (IV) every 4 hours separated by 1 week. This dose and schedule IL-2 identical to those used in a previous combined lymphokine-activated killer (LAK) cell phase II clinical trial the IL-2/LAK Working Group. Patient eligibility criteria, management guidelines similar trial. Forty-six assessable for response. Objective responses observed 10 46 (two...